Fortress Biotech, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Net Income (Loss) per Common Share (Tables)

Net Income (Loss) per Common Share (Tables)

9 Months Ended

Sep. 30, 2026

Net Income (Loss) per Common Share

Schedule of Potentially Dilutive Securities are Excluded from the Computation of Net Income (Loss) Per Common Share



		September 30,
		2026		2025
Warrants to purchase Common Stock		5,822,037		13,050,619
Options to purchase Common Stock		—		18,896
Unvested Restricted Stock and deferred Restricted Stock		239,459		2,368,386
Unvested Restricted Stock units and deferred Restricted Stock units		1,253,417		2,748,772
Total		7,314,913		18,186,673

Schedule of Weighted Average Number of Shares


		Three Months Ended September 30,						Nine Months Ended September 30,
($ in thousands, except share and per share amounts)		2026				2025		2026				2025
Net income (loss) attributable to common stockholders		$	(7,853)		$	3,675		$	98,036		$	4,316
Weighted average common shares outstanding - basic			33,746,832			27,244,474			33,394,537			27,075,216
Dilutive effect of potential common shares			—			5,856,487			5,602,976			3,620,780
Weighted average common shares outstanding - diluted			33,746,832			33,100,961			38,997,513			30,695,996

Net income (loss) per common share attributable to common stockholders - basic		$	(0.23)		$	0.13		$	2.94		$	0.16
Net income (loss) per common share attributable to common stockholders - diluted		$	(0.23)		$	0.11		$	2.51		$	0.14